Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence AAHLPAEFTPAVHASLDKF
Primary information
sequence IDSeq_45
Peptide sequenceAAHLPAEFTPAVHASLDKF
CancerPDF_ID CancerPDF_ID3479, CancerPDF_ID3694, CancerPDF_ID10428,
PMID27026199,27026199,21805675
Protein NameHemoglobin subunit alpha,Hemoglobin subunit alpha,Hemoglobin subunit alpha
UniprotKB Entry NameHBA_HUMAN,HBA_HUMAN,HBA_HUMAN
FluidUrine,Urine,Urine
M/ZNA,NA,2022.0399
ChargeNA,NA,NA
Mass (in Da)NA,NA,NA
fdr2021.03,2021.04,NA
Profiling Technique"CE-MS, Micro-TOF-MS","CE-MS, Micro-TOF-MS",MALDI-TOF
Peptide Identification techniqueMS-MS,MS-MS,MALDI-TOF-MS
Quantification TechniqueNA,NA,NA
Labelled/Label FreeLabel Free,Label Free,Label Free
FDRNA,NA,1
CancerPDF_ID CancerPDF_ID3479, CancerPDF_ID3694, CancerPDF_ID10428,
p-Valueless than 0.05,less than 0.05,NA
SoftwareProteome Discoverer 1.2,Proteome Discoverer 1.2,NA
Length19,19,19
Cancer TypeBladder cancer,Bladder cancer,Muscle-invasive bladder cancer
DatabaseUniprot Human non-redundant Database,Uniprot Human non-redundant Database,SwissProt Database
ModificationNA,NA,NA
Number of Patients451 for training (341 patients and 110 normal) and 270 for testing(168 primary UBC patients and 102 normal controls);, 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls),751 bladder cancer and 127 control
RegulationDifferentially expressed between primary UBC and normal individual,Differentially expressed between recurrence of UBC vs recurrence control,Differentially expressed between cancer vs normal samples
ValidationIndependent Validation,Independent Validation,Mann-Whitney tests and areas under receiver-operator characteristic
SensitivityFor testing dataset 91%,For testing dataset 88%,NA
SpecificityFor testing dataset 68%,For testing dataset 51%,NA
AccuracyFor testing dataset 76%,NA,NA
Peptide AtlasPeptideAtlas
IEDB119732 144183